S&P may cut Talecris Biotherapeutics

Standard & Poor's said it placed its BB debt rating on Talecris Biotherapeutics Inc.'s $600 million senior unsecured notes due 2016 on CreditWatch with negative implications.

This action followed news that Grifols plans to acquire Talecris in a $3.4 billion deal, S&P said.

The agency said it plans to withdraw its BB corporate credit rating on Talecris following the close of the transaction.

The top five major players in the blood plasma-derived pharmaceutical industry dominate the field. Talecris is currently the third-largest and Grifols the fifth-largest company in the industry, the agency said.

When combined, the company will be the third-largest player by a significant margin in an industry in which economies of scale are important, S&P said.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.